Fierce Pharma30m
After patient death, Sarepta and Roche pause 3 trials of gene therapy Elevidys in Europe
In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...
Sarepta falls after news about clinical hold request related to Elevidys trials
Sarepta Therapeutics (SRPT) stock drops as the EU officials request a clinical hold on trials involving its gene therapy ...
BioSpace1h
Sarepta’s Duchenne Gene Therapy Placed on Hold in Europe Pending Death Investigation
The European Medicines Agency asked for three clinical trials to be placed on hold until the exact cause of death of a US ...
Investor's Business Daily on MSN1h
Sarepta Dives On 'Another Unfortunate Development' For Its Gene Therapy
Sarepta stock tumbled Thursday after European officials put all studies of the company's gene therapy, Elevidys, on hold.
pharmaphorum3h
Multiple studies of Sarepta's DMD therapy halted after death
The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene ...
The Pharma Letter5h
EMA halts Sarepta’s DMD gene therapy trial after patient death
The European Medicines Agency has temporarily suspended enrollment and dosing in a Phase II trial of Sarepta Therapeutics' ...
Neurology Advisor6d
Patient Dies Following Treatment With DMD Gene Therapy Elevidys
Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.
STAT1h
Pharmaceuticals are spared from tariffs, for now
President Trump yesterday announced a baseline tariff of 10% on all imported products and higher rates on certain countries ...
ET HealthWorld13h
Parents of muscular dystrophic patients protest in Delhi, demand access to high-cost treatment
One of the demands raised during the protests was access to 'Elevidys', a one-time gene therapy treatment that has the ...
StockStory.org on MSN2d
Why Sarepta Therapeutics (SRPT) Stock Is Nosediving
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...
Sarepta price target lowered to $179 from $210 at BofA
BofA lowered the firm’s price target on Sarepta (SRPT) to $179 from $210 and keeps a Buy rating on the shares. Following the news of the departure of Peter Marks from the FDA’s Center for Biologics ...